Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

9 Meters Biopharma, Inc. (NMTR)

0.3033   0.01 (3.37%) 08-18 07:52
Open: 0.2975 Pre. Close: 0.2934
High: 0.315 Low: 0.28
Volume: 1,537,067 Market Cap: 79(M)
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.32 - 0.32 0.32 - 0.32
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.3 - 0.3 0.3 - 0.3

Technical analysis

as of: 2022-08-17 4:25:26 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.36     One year: 0.42
Support: Support1: 0.24    Support2: 0.2
Resistance: Resistance1: 0.31    Resistance2: 0.36
Pivot: 0.25
Moving Average: MA(5): 0.28     MA(20): 0.25
MA(100): 0.39     MA(250): 0.74
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 89.2     %D(3): 85.1
RSI: RSI(14): 59.9
52-week: High: 1.46  Low: 0.19
Average Vol(K): 3-Month: 4,634 (K)  10-Days: 2,347 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NMTR ] has closed below upper band by 6.3%. Bollinger Bands are 41.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Mon, 15 Aug 2022
9 Meters Biopharma GAAP EPS of -$0.04 in-line (NASDAQ:NMTR) - Seeking Alpha

Mon, 15 Aug 2022
9 METERS BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

Mon, 15 Aug 2022
2022-08-15 | NDAQ:NMTR | Press Release | 9 Meters Biopharma Inc. - Stockhouse

Thu, 28 Jul 2022
$NMTR 9 Meters Biopharma Files Prospectus Relates To Possible Resale Of Up To 144.6 Million Shares Of Common Stock From Time To Time By Selling Stockholders - CML News

Thu, 30 Jun 2022
9 Meters stock falls despite drug showing promise in short bowel syndrome trial - Seeking Alpha

Mon, 13 Jun 2022
9 Meters Biopharma to Participate in the 2022 BIO International Convention - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 256 (M)
Shares Float 241 (M)
% Held by Insiders 4 (%)
% Held by Institutions 27.6 (%)
Shares Short 5,140 (K)
Shares Short P.Month 16,460 (K)

Stock Financials

EPS -0.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -58.6
Return on Equity (ttm) -131.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.15
Qtrly Earnings Growth 0
Operating Cash Flow -33 (M)
Levered Free Cash Flow -21 (M)

Stock Valuations

PE Ratio -2.07
PEG Ratio 0
Price to Book value 1.59
Price to Sales 0
Price to Cash Flow -2.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.